Skip to content

Rapid detecting familiar pathogensin lower respiratory tract infections with nucleic acid testing in AECOPD patients

Rapid detecting familiar pathogensin lower respiratory tract infections with nucleic acid testing in AECOPD patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036784
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Gold Standard:Clinical outcome
on&#32
the&#32
blast&#32
verification,&#32
used&#32
RPA&#32
and&#32
technology&#32
to&#32
acid&#32

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged over 40 years male or female; 2. According to the chronic obstructive pulmonary disease guidelines (2018 edition) , after inhalation of Bronchodilator, FEV1FVC <70% were the diagnostic criteria of chronic obstructive pulmonary disease, and 200 patients with chronic obstructive pulmonary disease were selected; 3. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is defined as dyspnea, cough, increased sputum or purulent sputum at night, exceeding the daily variation, according to the consensus of Chinese experts on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)(revised edition 2017), patients who need to change their treatment.

Exclusion criteria

Exclusion criteria: 1. Unable to cooperate with the patient to take the qualified deep part sputum specimen. 2. Sputum Culture confirmed that lower respiratory tract infection was the most common pathogen except for other pathogens. 3. Rule out acute pulmonary edema, acute pulmonary embolism, acute heart failure, Arrhythmia, and other heart and lung diseases; 4. Rule out the combination of tumor, autoimmune disease, etc. 5. Patients with asthma, tuberculosis, Interstitial lung disease, and other chronic lung diseases were excluded.

Design outcomes

Primary

MeasureTime frame
Characteristic sequence detection of pathogenic bacteria nucleic acid;MMAC score;Arterial blood gas analysis;Pathogen detection time;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
Length of stay;medical expense;

Countries

China

Contacts

Public ContactJina Ma

Shanghai Pulmonary Hospital

majian_723@sina.com+86 13916325637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026